GATA3 expression in advanced breast cancer: prognostic value and organ-specific relapse.

OBJECTIVES GATA3 is a transcription factor regulating luminal cell differentiation in the mammary glands and has been implicated in the luminal types of breast carcinoma. The prognostic significance of GATA3 in breast cancer remains controversial. METHODS In this study, we assessed the prognostic value of the molecule in a subset of 62 advanced breast cancers and 10 control breast cancers (no metastasis after follow-up). RESULTS GATA3 expression levels in luminal tumors of advanced stage were significantly higher than that of the human epidermal growth factor receptor 2 (HER2) subtype and triple-negative carcinomas, as expected, but were similar to those of the luminal controls. Furthermore, 88% of nonluminal tumors showed variable GATA3 expression, for which the HER2 subtype had significantly higher GATA3 expression than that of the triple-negative carcinomas. Interestingly, GATA3 levels were significantly lower in carcinomas with lung relapse compared to those with metastatic recurrence to other organs, thus reflecting the findings in animal models. No significant difference was observed between tumors with bone relapse and those metastasized to nonskeletal sites. Moreover, high GATA3 expression was significantly associated with favorable relapse-free survival and overall survival. CONCLUSIONS These findings suggest that GATA3 may not act solely as a luminal differentiation marker, and further uncovering the molecular pathways by which GATA3 regulates the downstream targets will be crucial to our understanding of breast cancer dissemination.

[1]  Z. Werb,et al.  GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. , 2008, Cancer cell.

[2]  J. Palazzo,et al.  The significance of GATA3 expression in breast cancer: a 10-year follow-up study. , 2009, Human pathology.

[3]  Marc K Halushka,et al.  GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas. , 2013, Human pathology.

[4]  M. Wilkerson,et al.  Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas. , 2012, American journal of clinical pathology.

[5]  Charles M Perou,et al.  CDK inhibitor p18(INK4c) is a downstream target of GATA3 and restrains mammary luminal progenitor cell proliferation and tumorigenesis. , 2009, Cancer cell.

[6]  Haiyan I. Li,et al.  Purification and unique properties of mammary epithelial stem cells , 2006, Nature.

[7]  G. Siegal,et al.  Breast carcinomas with isolated bone metastases have different hormone receptor expression profiles than those with metastases to other sites or multiple organs. , 2011, Annals of diagnostic pathology.

[8]  C. Sweeney,et al.  Significance of GATA-3 expression in outcomes of patients with breast cancer who received systemic chemotherapy and/or hormonal therapy and clinicopathologic features of GATA-3-positive tumors. , 2013, Human pathology.

[9]  E. Lam,et al.  Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours , 2009, Breast Cancer Research.

[10]  Debashis Ghosh,et al.  Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. , 2005, Cancer research.

[11]  Zena Werb,et al.  GATA-3 Maintains the Differentiation of the Luminal Cell Fate in the Mammary Gland , 2006, Cell.

[12]  Georgia Chenevix-Trench,et al.  Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2- or sporadic breast tumors , 2008, Breast Cancer Research and Treatment.

[13]  Anita Grigoriadis,et al.  Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles , 2013, Modern Pathology.

[14]  S Michiels,et al.  Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  Steve Horvath,et al.  Higher levels of GATA3 predict better survival in women with breast cancer. , 2010, Human pathology.

[16]  Edi Brogi,et al.  ID genes mediate tumor reinitiation during breast cancer lung metastasis , 2007, Proceedings of the National Academy of Sciences.

[17]  Marie-Liesse Asselin-Labat,et al.  Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation , 2007, Nature Cell Biology.

[18]  C. Perou,et al.  How many etiological subtypes of breast cancer: two, three, four, or more? , 2014, Journal of the National Cancer Institute.

[19]  Y. Matsuno,et al.  Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer , 2014, Breast Cancer Research and Treatment.

[20]  Z. Ren,et al.  Breast cancer subtypes predispose the site of distant metastases. , 2015, American journal of clinical pathology.

[21]  J. Prichard,et al.  Immunohistochemical evaluation of GATA-3 expression in ER-negative breast carcinomas. , 2014, American journal of clinical pathology.

[22]  Z. Werb,et al.  GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression , 2013, Nature Cell Biology.

[23]  H. Turna,et al.  Clinicopathologic and prognostic evaluation of invasive breast carcinoma molecular subtypes and GATA3 expression. , 2010, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[24]  Wei Yan,et al.  GATA3 Inhibits Breast Cancer Metastasis through the Reversal of Epithelial-Mesenchymal Transition* , 2010, The Journal of Biological Chemistry.

[25]  Jeffrey E. Green,et al.  Expression of GATA3 in MDA-MB-231 Triple-negative Breast Cancer Cells Induces a Growth Inhibitory Response to TGFß , 2013, PloS one.

[26]  R. Strausberg,et al.  Mutation of GATA3 in human breast tumors , 2004, Oncogene.

[27]  Z. Werb,et al.  GATA3 in development and cancer differentiation: Cells GATA have it! , 2010, Journal of cellular physiology.

[28]  Brian J. Wilson,et al.  GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis , 2009, Oncogene.

[29]  François Vaillant,et al.  Generation of a functional mammary gland from a single stem cell , 2006, Nature.

[30]  D. Nonaka,et al.  A study of immunohistochemical differential expression in pulmonary and mammary carcinomas , 2010, Modern Pathology.

[31]  Y. Tamaki,et al.  Clinicopathological analysis of GATA3-positive breast cancers with special reference to response to neoadjuvant chemotherapy. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  Z. Ren,et al.  Prognostic factors in patients with metastatic breast cancer at the time of diagnosis. , 2014, Pathology, research and practice.

[33]  Fang Liu,et al.  Estrogen receptor-related genes as an important panel of predictors for breast cancer response to neoadjuvant chemotherapy. , 2011, Cancer letters.

[34]  T. Nielsen,et al.  GATA-3 Expression in Breast Cancer Has a Strong Association with Estrogen Receptor but Lacks Independent Prognostic Value , 2008, Cancer Epidemiology Biomarkers & Prevention.

[35]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.